Experienced in Pseudomyxoma Peritonei

Dr. Laith Abushahin

Oncology
3410 Worth Street, Suite 400, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
19 Years of Experience
Experienced in Pseudomyxoma Peritonei
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laith Abushahin is an Oncologist in Dallas, Texas. Dr. Abushahin has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatic Ductal Adenocarcinoma.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Jordan, 2006
Residency
Internal Medicine Medical Oncology, University of Arizona College of Medicine GME
Specialties
Oncology
Licenses
Internal Medicine in IA
Fellowships
Medical Oncology, Baylor University Medical Center
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Gemcitabine
Study Phase: Phase 1
View 7 Less Clinical Trials

18 Total Publications

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Journal: Future oncology (London, England)
Published: May 17, 2022
Similar Doctors
Advanced in Pseudomyxoma Peritonei
Dr. Jayanthi S. Lea
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Pseudomyxoma Peritonei
Dr. Jayanthi S. Lea
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Of Texas Southwestern Medical Center At Dallas

600 S Main St, 
Fort Worth, TX 
 (32.0 miles away)
817-882-2400
Languages Spoken:
English
See accepted insurances

Jayanthi Lea is a Gynecologic Oncologist and an Oncologist in Fort Worth, Texas. Dr. Lea is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

Advanced in Pseudomyxoma Peritonei
Dr. Deette R. Vasques
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Pseudomyxoma Peritonei
Dr. Deette R. Vasques
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Oncology-Hematology Consultants PA

6100 Harris Pkwy, Suite 235, 
Fort Worth, TX 
 (38.4 miles away)
817-759-7000
Languages Spoken:
English, Hindi, Mandarin, Spanish, Taiwanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Deette Vasques is a Gynecologic Oncologist and an Oncologist in Fort Worth, Texas. Dr. Vasques is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Vulvectomy, and Ureteroscopy. Dr. Vasques is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Syed M. Kazmi
Hematology Oncology | Hematology | Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Syed M. Kazmi
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

3030 Waterview Pkwy, 
Richardson, TX 
 (14.4 miles away)
972-669-7070
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Syed Kazmi is a Hematologist Oncology specialist and a Hematologist in Richardson, Texas. Dr. Kazmi is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Gastroesophageal Junction Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abushahin's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile